1
Materials
Design
Analysis
Reporting (MDAR)
Checklist for Authors
The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences
(see Statement of Task: doi:10.31222/osf.io/9sm4x.
). The MDAR checklist is a tool for authors, editors and others seeking to ad
opt
the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration
Document for additional context for the MDAR framework.
2
Materials
Antibodies
Yes (indicate where provided: page
no/section/legend)
n/a
For commercial reagents, provide supplier
name, catalogue number and RRID, if available.
R&D Systems AF648
RRID:AB_355504
p. S6
-
7
Abcam ab6301[15B8]
RRID:AB_305406
p. S6
-7
ThermoFisher A21447
RRID:AB_141844
p. S6
-7
ThermoFisher A21202
RRID:AB_141607
p. S6
-
7
Cell materials
Yes (indicate where provided: page
no/section/legend)
n/a
Cell lines:
Provide species information, strain.
Provide accession number in repository
OR
supplier name, catalog number, clone number,
OR
RRID
ATCC CRL
-
1821
RRID:CVCL_9108
p. S2
Primary cultures:
Provide species, strain, sex of
origin, genetic modification status
.
n/a
Experimental animals
Yes (indicate where provided: page
no/section/legend)
n/a
Laboratory animals:
Provide species, strain, sex, age,
genetic modification status
.
Provide
a
ccession
number in repository
OR
supplier name, catalog
number, clone number,
OR
RRID
n/a
Animal observed in or captured from the
field:
Provide species, sex and age where
possible
n/a
Model organisms:
Provide Accession number
in repository (where relevant)
OR
RRID
RRID:BDSC_90853
p.S8
RRID:BDSC_90854
p.S8
Plants and microbes
Yes (indicate where provided: page
no/section/legend)
n/a
Plants:
provide species and strain, unique accession
number if available, and source (including location
for collected wild specimens)
n/a
Microbes:
provide species and strain, unique
accession number if available, and source
n/a
Human research
participants
Yes (indicate where provided: page
no/section/legend)
n/a
Identify authority granting ethics approval (IRB or
equivalent committee(s), provide reference number
for approval.
n/a
Provide statement confirming informed consent
obtained from study participants.
n/a
Report on age and sex for all study
participants.
n/a
3
Design
Study protocol
Yes (indicate where provided: page
no/section/legend)
n/a
For clinical trials, provide the trial registration
number
OR
cite DOI in manuscript.
n/
a
Laboratory protocol
Yes (indicate where
provided: page
no/section/legend)
n/a
Provide DOI or other citation details if detailed step
-
by
-step protocols are available.
n/
a
Experimental study design (statistics details)
Yes (indicate where provided: page
no/section/legend)
n/a
State whether and how the following have been
done
, or
if they were not carried out.
Sample size determination
n/
a
Randomisation
n/
a
Blinding
n/
a
Inclusion/exclusion criteria
n/
a
Sample definition and
in
-
laboratory replication
Yes (indicate where provided: page
no/section/legend)
n/a
State number of times the experiment was
replicated in laboratory
Details for each experiment are provided in text and
material and methods. All data are available on
https://doi.org/10.22002/D1.1444
Define whether data describe technical or biological
replicates
Details for each experiment are provided in text and
material and methods, p. S2
-S10
Ethics
Yes (indicate where provided: page
no/section/legend)
n/a
Studies involving human participants: State details of
authority granting ethics approval (IRB or equivalent
committee(s), provide reference number for
approval.
n/
a
Studies involving experimental animals: State details
of
authority granting ethics approval (IRB or
equivalent committee(s), provide reference number
for approval.
n/
a
Studies involving specimen and field samples: State if
relevant permits obtained, provide details of
authority approving study; if none were required,
explain why.
n/
a
Dual Use Research of Concern (DURC)
Yes (indicate where provided: page
no/section/legend)
n/a
If
study is subject to dual use research of
concern,
state
the authority granting approval and reference
number for the regulatory approval
n/
a
4
Analysis
Attrition
Yes (indicate where provided: page
no/section/legend)
n/a
State if sample or data point from the analysis is
excluded, and whether the criteria for exclusion were
determined and specified in advance.
Exclusion criteria are described in the materials and
methods. p. S2
-S10
Statistics
Yes (indicate where provided: page
no/section/legend)
n/a
Describe statistical tests used and justify choice of
tests.
p. S2
-
S1
6
, Materials and
methods and supplemental text
Data Availability
Yes (indicate where provided: page
no/section/legend)
n/a
State whether newly created datasets are available,
including protocols for access or restriction on
access.
All data is available
If
data are publicly available, provide accession
number in repository or DOI or URL.
https://doi.org/10.22002/D1.1444
If publicly available data are reused, provide
accession number in repository or DOI or URL, where
possible.
n/
a
Code
Availability
Yes (indicate where provided: page
no/section/legend)
n/a
For all newly generated code and software essential
for replicating the main findings of the study:
State whether the code or software is available.
All code is available
If
code is publicly available, provide accession
number in repository, or DOI or URL.
https://doi.org/10.22002/D1.1444
Reporting
Adherence to community standards
Yes (indicate where provided: page no/section/legend)
n/a
MDAR framework recommends adoption of
discipline
-specific guidelines, established and
endorsed through community initiatives. Journals
have their own policy about requiring specific
guidelines and recommendations to complement
MDAR.
State if
relevant guidelines (eg., ICMJE, MIBBI,
ARRIVE) have been followed, and whether a checklist
(eg., CONSORT, PRISMA, ARRIVE) is provided with
the manuscript.
n/
a